Show simple item record

dc.contributor.authorRobertson, Jane D
dc.contributor.authorNagesh, K
dc.contributor.authorJowitt, S N
dc.contributor.authorDougal, Mark
dc.contributor.authorAnderson, Heather
dc.contributor.authorMutton, K
dc.contributor.authorZambon, M
dc.contributor.authorScarffe, J Howard
dc.date.accessioned2009-11-23T10:15:05Z
dc.date.available2009-11-23T10:15:05Z
dc.date.issued2000-04
dc.identifier.citationImmunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. 2000, 82 (7):1261-5 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid10755398
dc.identifier.doi10.1054/bjoc.1999.1088
dc.identifier.urihttp://hdl.handle.net/10541/86660
dc.description.abstractVaccination against influenza and Streptococcus pneumoniae is recommended for elderly and immunocompromised individuals. However, there is little information concerning the efficacy of vaccination in specific groups of patients. In this study, 52 patients underwent vaccination against influenza, S. pneumoniae and Haemophilus influenzae type b (Hib) as they attended hospital outpatient clinics. Serum was analysed prior to vaccination and 4-6 weeks afterwards. Antibody titres against S. pneumoniae and Hib were compared with reference values corresponding to the geometric mean titres of a healthy UK population. For influenza vaccination, haemagglutination inhibition (HI) titres were measured against three inactivated strains; a titre of > or = 1/40 was considered protective. No patient had protective titres to all three antigens prior to vaccination and 41 patients (85%) had titres < 1/40 to all 3 strains. Post vaccination only 9/48 patients (19%) achieved protective antibody titres. Resistance to S. pneumoniae and response to Pneumovax II was also poor: prevaccination, 45 patients (93%) had suboptimal antibody titres and in 26/43 patients (61%) titres remained low post vaccination. Resistance to Hib and response to vaccination was comparable with the healthy adult UK population. These results question the practice of routine influenza and pneumococcal vaccination in myeloma patients.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibody Formation
dc.subject.meshFemale
dc.subject.meshHaemophilus Infections
dc.subject.meshHaemophilus Vaccines
dc.subject.meshHaemophilus influenzae
dc.subject.meshHumans
dc.subject.meshImmunocompromised Host
dc.subject.meshInfluenza Vaccines
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMultiple Myeloma
dc.subject.meshPneumococcal Infections
dc.subject.meshStreptococcus pneumoniae
dc.subject.meshVaccination
dc.titleImmunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Trust, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
refterms.dateFOA2020-04-21T14:47:21Z
html.description.abstractVaccination against influenza and Streptococcus pneumoniae is recommended for elderly and immunocompromised individuals. However, there is little information concerning the efficacy of vaccination in specific groups of patients. In this study, 52 patients underwent vaccination against influenza, S. pneumoniae and Haemophilus influenzae type b (Hib) as they attended hospital outpatient clinics. Serum was analysed prior to vaccination and 4-6 weeks afterwards. Antibody titres against S. pneumoniae and Hib were compared with reference values corresponding to the geometric mean titres of a healthy UK population. For influenza vaccination, haemagglutination inhibition (HI) titres were measured against three inactivated strains; a titre of > or = 1/40 was considered protective. No patient had protective titres to all three antigens prior to vaccination and 41 patients (85%) had titres < 1/40 to all 3 strains. Post vaccination only 9/48 patients (19%) achieved protective antibody titres. Resistance to S. pneumoniae and response to Pneumovax II was also poor: prevaccination, 45 patients (93%) had suboptimal antibody titres and in 26/43 patients (61%) titres remained low post vaccination. Resistance to Hib and response to vaccination was comparable with the healthy adult UK population. These results question the practice of routine influenza and pneumococcal vaccination in myeloma patients.


Files in this item

Thumbnail
Name:
91420.pdf
Size:
194.0Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record